Breast (Oct 2021)

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations

  • Fabio Conforti,
  • Laura Pala,
  • Eleonora Pagan,
  • Elena Guerini Rocco,
  • Vincenzo Bagnardi,
  • Emilia Montagna,
  • Giulia Peruzzotti,
  • Tommaso De Pas,
  • Caterina Fumagalli,
  • Silvana Pileggi,
  • Chiara Pesenti,
  • Sergio Marchini,
  • Giovanni Corso,
  • Caterina Marchio’,
  • Anna Sapino,
  • Rossella Graffeo,
  • Laetitia Collet,
  • Philippe Aftimos,
  • Christos Sotiriou,
  • Martine Piccart,
  • Richard D. Gelber,
  • Giuseppe Viale,
  • Marco Colleoni,
  • Aron Goldhirsch

Journal volume & issue
Vol. 59
pp. 94 – 101

Abstract

Read online

Background: We report here for the first time, a comprehensive characterization of biological and clinical features of early-stage triple negative Invasive Lobular Carcinomas(TN-ILCs) Methods: We analyzed all consecutive patients with early-stage TN-ILC operated at two reference cancer-centers between 1994 and 2012.Primary objective was to assess the invasive disease-free survival(iDFS).Co-primary objective was to assess biological features of TN-ILCs, including molecular intrinsic subtypes based on PAM-50 assay, expression of androgen receptor (AR) and mutational status of ERBB2-gene.Additionally, DNA mutational status of an independent cohort of 45 TN-ILCs from three databases were analyzed, to confirm mutations in ERBB2-gene and to identify other recurrently mutated genes. Results: Among 4152 ILCs, 74(1.8%) were TN and were analyzed.The iDFS at 5 and 10 years of FUP were 50.4%(95%CI,38.0–61.6) and 37.2%(95%CI,25.5–48.8), respectively.The molecular subtype was defined through PAM50-classifier for 31 out of 74 TN-ILCs: 48% were Luminal-A(15/31), 3% luminal-B(1/31), 32% HER2-enriched (10/31), and only 16% basal-like(5/31).Luminal tumors expressed AR more frequently than non-luminal tumors (AR≥1% in 94% of luminal tumors versus 53% in non-luminal tumors; p-value = 0.001).20% of TN-ILCs analyzed(7/35), harbored a pathogenetic and actionable mutation in the ERBB2-gene. Analysis of the independent cohort of 45 TN-ILCs from three different databases, confirmed similar percentage of pathogenetic and actionable mutations in ERBB2-gene(20%; 9/45).Among the top 10 molecular pathways significantly enriched for recurrently mutated genes in TN-ILCs(FDR<0.05), there were ErbB-signaling and DNA-damage-response pathways. Conclusions: TN-ILCs are rare tumors with poor prognosis. Their specific biological features require newly defined targeted therapeutic strategies

Keywords